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Abstract
Resveratrol is a naturally occurring product used in the prevention and treatment of 
various diseases by acting as a potent defensive antioxidant. Resveratrol can be used in 
various fields, but the use is limited due to its poor solubility and hence low bioavail-
ability. For overcoming this limitation, various drug delivery systems of resveratrol were 
developed. The aim of the novel drug delivery system (NDDS) is to provide a therapeu-
tic amount of drug to the target site to maintain the desired drug concentration. NDDS 
enhances the duration of therapeutic activity, increases plasma half-life, decreases the 
immunogenicity, increases the stability of biopharmaceuticals, improves the solubility of 
low molecular weight drugs so does the bioavailability, and has a potential of targeted 
drug delivery. However, they have their own advantages as well as limitations. This 
chapter focuses on: (1) general introduction to resveratrol and its various therapeutic 
uses, (2) pharmacokinetic- and bioavailability-related problems of resveratrol, and (3) 
general about various NDDS used in resveratrol formulations.
Keywords: microparticulate systems, cyclodextrin complex, solid lipid nanoparticles 
(SLNs), vesicular systems and polymeric micelles
1. Introduction
Natural products have been used in the prevention and treatment of diseases throughout history 
due to their wide acceptability. Among the various groups of natural products and plant metab-
olites that are available, resveratrol plays an important role in the treatment of various diseases 
by acting as a potent defensive antioxidant [1]. Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is 
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a natural phenol and a phytoalexin produced by several plants in response to injury by numer-
ous plants in response to damage. The molecular formula is C14H12O3 and molecular weight is MW 228.25 (Figure 1) [2]. Resveratrol is present in plants of families including Gnetaceae, 
Vitaceae, Cyperaceae, Dipterocarpaceae, and Leguminosae. A variety of food and food prod-
ucts such as grapes, wine, grape juice, cranberries, mulberries, cranberry juice, and peanuts 
contain resveratrol [3]. Resveratrol is a member of the stilbene family [4], characterized by two 
benzene rings linked through isopropyl moiety separated by a double bond [5]. Resveratrol 
plays a role in defense mechanism against various fungal, bacterial infections, viral, and dam-
age from exposure to ultraviolet radiation (UV), which is very well depicted in Table 1 [6]. 
Resveratrol also exhibits various therapeutic effects such as antiaging, neuroprotector, anti-
oxidant, cardio protector, etc. The method of drug delivery has significant consequences over 
the efficacy of the constituent [7]. Drug delivery systems (DDSs) emerged as a new strategy 
based on interdisciplinary approach combining polymer science, bioconjugate chemistry, 
pharmaceutics, and molecular biology. DDS increases drug bioavailability and the fraction of 
Sr. 
no
Role of resveratrol Mechanism of action Refs
1 Cardioprotective Inhibition of transforming growth factor (TGF-β1) and atrial 
natriuretic peptide (ANP), increase in nuclear factor (NF-kB) activity
[13, 14]
2 Antioxidant Neutralization and inhibition of reactive oxygen species (ROS), lipid 
peroxidation inhibition, and metal cations chelation
[10, 11]
3 Immunomodulatory Increase in CD4/CD8 ratio, T lymphocytes proliferation, and B cell-
mediated immune response, promotion of humoral immune response 
and improvement in the formation of antibody cells
[14]
4 Antihypertensive Inhibition of vascular nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase induction and inhibition of COX-2
[20]
5 Anticancer Suppression of protein kinase and suppression of NF-kB activation, 
suppression of protein kinase and suppression, induction of 
apoptosis, cell cycle arrest and suppression of growth factor receptor 
(GFR)-mediated pathway
[16]
6 Anti-inflammatory Inhibition of NF-kB and nitric oxide synthases (NOS) expression and 
also reduction in proinflammatory IL-1β, cytokines, TNF-α, and COX-2
[20–22]
Table 1. Mechanism of action of resveratrol for different activities.
Figure 1. Chemical structure of resveratrol.
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the drug accumulated in the required zone, and minimizes drug degradation, loss and harmful 
side effects. A variety of DDS are also available for resveratrol for modulating its delivery; for 
example, cyclodextrin complex; microparticulate systems; nanocarrier systems such as nano-
suspension and solid lipid nanoparticles; and vesicular system such as niosomes, liposomes, 
transferosomes and ethosomes, and nanosponges.
2. Medicinal uses
Plants containing resveratrol have been widely used as a potent antioxidant [8] and also use-
ful in the treatment of various disease [9] (Figure 2).
2.1. Antioxidant activity
Oxidative stress caused due to free radicals generated through endogenous and exogenous 
sources plays a significant role in the pathogenesis of a disease [10]. Resveratrol (RSV) also 
suppresses the action of the lipopolysaccharide, an inducible form of nitric oxide (NO) syn-
thase, through the vascular endothelium, established by a reduction in nitric oxide produc-
tion, also inhibiting the oxidation of the low-density lipoprotein (LDL) through the in vivo 
chelation of copper, therefore suggesting a potential role in the prevention of atherosclerosis 
and coronary heart disease [11]. The first antioxidant activity was reported by Frankel et al. 
of transresveratrol using different antioxidant assays including lipid peroxidation assay, 
2,2-diphenylpicrylhydrazyl (DPPH) radical scavenging assay, total antioxidant activity, 
hydrogen peroxide scavenging activity assay, and reducing power assay. The results show 
that resveratrol has 2 μmol higher scavenging activity for diphenylpicrylhydrazyl (DPPH) 
radical as compared to the control group [12].
2.2. Cardioprotective activity
Various scientific studies reveal that utilization of plant extracts containing polyphenols, 
especially resveratrol, and red wine decreases mortality of coronary heart disease [13]. 
Due to its potent antioxidant, resveratrol, showing an overall good cardioprotective effect 
by inhibiting the oxidation of low-density lipoprotein (LDL), promotes vasodilation, 
reduces platelet aggregation, and enhances endothelial nitric oxide synthase activity [1]. 
Figure 2. Medical benefits of resveratrol.
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Resveratrol was also showing potential effect on protecting cardiac and vascular tissues by 
reducing the accumulation of reactive oxygen species (ROS) in renal hypertensive rats [14].
2.3. Immunomodulatory activity
Resveratrol was found to increase B cell-mediated immune response, and also increases CD4/
CD8 ratio and T cell proliferation. Li et al. demonstrated immunomodulatory effect on mice 
with lymphocytic leukemia [15].
2.4. Anticancer activity
Cancer is a chronic disease with a high death rate. Carcinogenesis involves in accumula-
tion of cancer-regulating genes [16]. Various studies suggested that fruit- and vegetable-rich 
diet leads to reduced incidence of cancer due to presence of polyphenolic compounds [17]. 
Subramanian et al. showed the antiproliferative, proapoptotic along with antiangiogenic 
activity of resveratrol by performing different in vitro studies on wide tumor cell lines [18]. 
Similarly, Hu et al. discussed treatment of hepatocellular carcinoma with different com-
pounds such as curcumin, tanshinone II-A, quercetin, berberine, silibinin, resveratrol, and 
celastrol derived from Chinese herbal medicines [19].
2.5. Antihypertensive activity
Endothelium-dependent vasorelaxation improved using resveratrol. Researchers’ findings 
show that early treatment with resveratrol preserves endothelial function, decreases oxidative 
stress and superoxide dismutase activity, and gradually lowers the incidence of hypertension 
with the reduction in hydrogen peroxide levels [20].
2.6. Anti-inflammatory and vasorelaxing activity
Oxidative and inflammatory responses attenuate by polyphenols in various cells [21]. 
Activatation of microglia causes secreation of neurotoxic and proinfammatory mediators 
after brain injury. Zhang et al. studied the effect of resveratrol in inhibiting microglia [22]. 
Resveratrol was also found to decrease the synthesis of prostaglandin (PGE2) by inhibiting cyclooxygenase (COX-2) enzyme activity, thus useful in inflammation [23]. Anti-inflammatory 
activity of resveratrol in turbot (a fish species) in vertebrates carried out by Leiro et al. The 
results showed the drug-dependent inhibition of messenger ribonucleic acid (mRNA) pro-
duction, and increased tumor necrosis factor (TNF-α) and interleukins (IL-1β) pre-mRNA 
levels, thus proving its anti-inflammatory activity in vertebrates [24]. A vasorelaxation effect 
was observed by the activity of nitrous oxide (NO) by Zenebe et al. in red wine polyphenols 
on rat femoral artery [25]. Resveratrol is a multipurpose compound found in wine polyphe-
nol, that improves the endothelial function with NO and vasorelaxation effect [26].
2.7. Antimicrobial activity
Stilbenes have been studied broadly for their antimicrobial activities [27]. Paolillo et al. stud-
ied resveratrol using cells line (U937) and observed time and dose-dependent reduction in 
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NO level [28]. Another antibacterial study given by Paulo et al. has determined zone of inhibi-
tion and minimum inhibitory concentration (MIC) using different strains of gram-negative 
spiral-shaped bacillus of Helicobacter, H. pylori. Most of the strains show similar susceptibil-
ity patterns, and MIC was observed in range 25–100 μg/ml. The result shows that action of 
resveratrol in urease inhibition was found to be higher (90%), as compared to the positive 
control strains (<75%). Thus, the research confirmed that the antibacterial activity of resvera-
trol is due to urease inhibition [29].
2.8. Antidiabetic activity
Diabetes mellitus is a complex metabolic disease characterized by high concentration of blood 
glucose level and increased insulin resistance [30]. Su et al. carried out resveratrol treatment 
study on streptozotocin-induced diabetic rats, the results decrease in triglyceride concentra-
tion by 50.2 ± 3.2%, and plasma glucose level by 25.3 ± 4.2% was obtained on the fourteenth 
day after treatment. The drug also verifies a stimulatory effect on the glucose absorption by 
numerous cells including hepatocytes and adipocytes [31].
2.9. Radioprotective activity
Radiation exposure is a major problem of destruction of a living cell, which causes free radical 
generation and ROS activation. Different polyphenols have been studied for their radiopro-
tective activities [32]. Aziz et al. studied that ultraviolet-B radiation causing skin damage of 
mouse was prevented using resveratrol. Topical use of 10 μmol solution of resveratrol in 
200 μl acetone results in the inhibition of ornithine decarboxylase, increase in cellular prolif-
eration, and protein levels of epidermal COX-2 were observed, thus confirming the radiopro-
tective activity, which was mediated by programmed cell death and elimination of damaged 
cells [33].
2.10. Neurodegenerative diseases
2.10.1. Parkinson’s disease
Neurodegeneration is associated with various factors such as gene alteration, inflammation, 
oxidative stress, and mitochondrial dysfunction [34]. Okawara et al. observed resveratrol 
in mid-brain segment culture that shows a protective role of Wistar rats on dopaminergic 
neurons. Cytotoxicity of 1-methyl-4-phenyl pyridinium (MPP+) causes neurodegeneration, 
which was formed from the transformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 
Decrease in numbers of viable dopaminergic neurons was observed when segmented culture 
was applied with 30 μmol of MPP+, but when applied with resveratrol, dose-dependent pro-
tection of neurons, which was due to antioxidative activity [35].
3. Bioavailability and pharmacokinetic studies of resveratrol
The absorption, distribution, metabolism, and excretion (ADME) and other pharmacokinetic 
parameters of resveratrol are well implicated. Instead of high oral absorption (~75%). The oral 
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bioavailability is less than 1% because of extensive and fast metabolism in intestine and liver 
leading into sulfate and glucuronide metabolites [36]. Almeida et al. determined the pharma-
cokinetic and safety contour of resveratrol. Four groups of five males and five females each 
were taken. Any two random subjects of each group were administered with placebo, while 
the remaining eight were administered with 25, 50, 100, and 150 mg of resveratrol, six times 
daily for 13 doses. Several pharmacokinetic parameters were determined out of which the 
peak plasma concentration (C
max
) was found to be 0.8–1.5 h, whereas the mean C
max
 and mean 
area under the curve (AUC
0–t
) were found to be dose dependent and found to be increasing 
with increase in dose from 25 to 150 mg [37].
4. Solubility and bioavailability enhancement of resveratrol
The reported aqueous solubility of resveratrol is <1 mg/ml, which is a key shortcoming of the 
drug [38]. The metabolic studies of resveratrol showed an increase in bioavailability when 
aglycone form of resveratrol was administered in solution of hydroxypropyl b-cyclodextrin 
[39]. Different approaches such as formulation of microparticles to reduce size to micron level 
[40], complexation with cyclodextrins [41], formulation of various vesicular systems such as 
liposomes [42], niosomes [43, 52], transfersomes and ethosomes [44], formulation of different 
nanocarrier systems for example nanostructured lipid carriers (NLCs), solid lipid nanoparticles 
(SLN) [45], nanosuspension [46], and nanocapsules [47] have been implied to improve differ-
ent properties of resveratrol such as bioavailability, solubility, photo-sensitivity, and stability.
5. Drug delivery systems
The aim of novel drug delivery system (NDDS) is to provide a therapeutic amount of drug 
to the target site to maintain the desired drug concentration. NDDS enhances duration of 
therapeutic activity, increases plasma half-life, decreases the immunogenicity, increases the 
stability of biopharmaceuticals, improves the solubility of low molecular weight drugs so 
does the bioavailability, and has a potential of targeted drug delivery. Various NDDS given in 
Table 2 can be explained as follows:
5.1. Microparticulate systems
These systems act as the carrier vehicle system for solid or liquid microparticles surrounded 
by polymeric layer ranging from 0.1 to 200 μm [48] in diameter (Figure 3), the type of poly-
mer present in the layer improves bioavailability and controls the release of the drug [49]. 
Nam et al. improved the stability and antioxidant activity of the resveratrol possessing cyano-
groups by formulating its porous polymeric microspheres by dispersion polymerization. 
Antioxidant property was characterized by DPPH radical scavenging activity [50]. Das et al. 
formulated microparticles of resveratrol and pectin utilizing glutaraldehyde as hardening 
agent and zinc ions as crosslinking agent, as resveratrol has potential therapeutic activity 
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Sr. 
no.
Drug delivery systems Method of formulation Model used Observations Refs
1 Microparticulate 
systems
Microparticles prepared by 
using resveratrol and pectin, 
containing glutaraldehyde 
as hardening agent and zinc 
ions as cross-linking agent 
for pectin
In vitro and in vivo 
drug release. Plasma 
appearance (C
p
) of 
drug was delayed 
for 4–5 h in direct 
administration into 
stomach
Result shows 
enhancement of 
antioxidant activity 
and improved stability 
of resveratrol in 
microparticulate 
system as compared to 
that of pure resveratrol
[54, 56]
2 Microcapsules Microparticles of resveratrol 
were prepared by 
microencapsulation using 
yeast cells
In vitro Yeast-encapsulated 
resveratrol formulation 
shows increased 
stability, solubility, 
bioavailability and 
sustained-release 
profile
[6]
3 Cyclodextrin complex Inclusion complexes 
prepared using combination 
of resveratrol with 
β-cyclodextrins and 
hydroxyl-β-cyclodextrins
In vitro Enhanced solubility, 
antioxidant activity, 
and thermal stability
[59, 60]
4 Solid lipid 
nanoparticles
Lipid nanoparticles of 
resveratrol were prepared 
by using modified hot 
homogenization technique
In vitro Results show increased 
oral bioavailability 
of poorly soluble 
compounds
[42]
5 Nanosuspension Nanosuspension of 
resveratrol was prepared 
by using high-pressure 
homogenization technique
In vitro High solubility and 
dissolution velocity, 
thus increasing the 
bioavailability
[43]
6 Vesicular systems 
liposomes
Liposomes was prepared by 
using Phosphatidylcholine 
(PC) and resveratrol were 
dissolved in mixture 
solvents such as chloroform 
and methanol using rota 
evaporator. The liposome 
suspension was then added 
dropwise to chitosan solution 
with stirring and then 
solution left overnight at 
4°C. Finally, chitosan-coated 
liposomes were harvested 
using centrifugation
In vitro Increased skin-
permeation efficiency 
with effective 
transdermal delivery 
system
[66]
7 Niosomes Resveratrol-loaded niosomes 
were prepared using two 
stage techniques that 
include mechanical agitation 
followed by sonication, 
where two different 
surfactants, span 80 and span 
60, were used
In vitro Results show increased 
stability and improved 
the bioavailability
[66]
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Figure 3. Microparticulate system.
Sr. 
no.
Drug delivery systems Method of formulation Model used Observations Refs
8 Transfersome and 
ethosomes
Transfersomes and ethanol-
containing vesicles were 
prepared by thin lipid film 
hydration method (rota 
evaporator)
In vitro and 
permeation studies 
(porcine skin 
carried out on Franz 
diffusion cells)
Findings show that 
nanocarriers were 
found to possess 
an encapsulation 
efficiency of >70% with 
a mean diameter of 
83–116 nm
[67]
9 Nanosponges Nanosponges containing 
resveratrol were prepared by 
solubilizing the reagents in 
dimethyl sulfoxide (DMSO) 
at 100°C for 4 h
In vitro and 
permeation studies 
(pigskin)
Results increase the 
stability, cytotoxicity, 
and permeation of 
resveratrol. Decrease 
in crystallinity of 
resveratrol was 
observed after 
encapsulation
[65]
10 Microspheres Microspheres of resveratrol 
(Res) using chitosan were 
prepared by emulsion 
chemical crosslinking 
method, and vanillin was 
used as the new crosslinker
Higuchi was the 
most suitable model 
for the controlled 
release profile
Microspheres of 
resveratrol were 
protected from light 
and heat as compared 
to free Res, and 
increase in stabilization 
of Res was achieved 
through crosslinking 
with vanillin
[67]
Table 2. Novel drug delivery systems for resveratrol (RSV) delivery.
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on colitis and colon cancer, and was used as a model drug in the prepared formulation. By 
fluctuating the formulation variables, a variety of microparticles were prepared, which were 
investigated on different shape and size of the microparticles, weight loss during drying, 
moisture content, encapsulation efficiency, drug release pattern from the microparticles, 
and swelling-erosion ratio. The formed microparticles were spherical with less than 1 mm 
diameter and with greater than 94% encapsulation efficiencies. Colon-specific in vivo and in 
vitro drug release was shown by glutaraldehyde-modified microparticles (GMM) formulated 
at optimized conditions. GMM delayed the plasma appearance of the drug for 4–5 h after 
their administration straightaway into stomach, but the AUC was comparable to other control 
formulations of the experiment; this indicated the potential of the developed microparticle 
formulation of the resveratrol as a colon-specific drug delivery system [51].
5.2. Microcapsules
Microencapsulation is a technique in which tiny particles are enclosed by a coating to give 
small capsules (Figure 4). Microencapsulation can also be used to enclose solids, liquids, or 
gases surrounded by a hard or soft soluble film, in order to decrease dosing frequency and 
avoid the degradation of pharmaceuticals. Encapsulation of resveratrol was done by the yeast 
cell, which was characterized by FT-IR spectra, fluorescence and confocal micrographs of 
the microcapsules, yeast cells, and resveratrol. The release of the drug was characterized in 
simulated gastric fluid (SGF), and storage stability was determined by taking powder sample 
of the formed microcapsules at 25°C at 75% RH, 25°C at 90% RH, and 60°C under the dark 
or laboratory fluorescent lighting conditions. It was found that the encapsulated resveratrol 
possess high scavenging capacity on DPPH radical as compared to nonencapsulated resve-
ratrol. The encapsulation does not cause any chemical change in the active moiety. Besides, 
the encapsulation enhances the DPPH radical-scavenging activity, stability, sustained-release 
and also solubility of resveratrol and so it’s bioavailability [52].
5.3. Cyclodextrin complex
Cyclodextrins are cyclic oligosaccharides formed during bacterial digestion of cellulose. They 
are also known as cycloamyloses, cyclomaltoses, and Schrodinger dextrins. These complexes 
have a lipophilic core with hydrophilic outer surface and hence capable to form inclusion 
Figure 4. Microcapsules.
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complexes and holding lipophilic drugs to their inner cavity (Figure 5). Thus, they improve 
solubility and so does the bioavailability of the poorly soluble drugs. These can be divided 
into α, β, and γ subtypes on the basis of presence of six, seven, or eight glucopyranose units, 
respectively. Cyclodextrins protect the drug from oxidation so act as a controlled dosage reser-
voir [53, 54]. Resveratrol is encapsulated in different native and modified cyclodextrins to form 
different inclusion complexes to enhance its poor aqueous solubility [55]. Lu et al. observed 
enhancement in aqueous solubility and antioxidant property of resveratrol by forming inclu-
sion complex of resveratrol with β-cyclodextrins and hydroxyl-β-cyclodextrins. The drug 
and cyclodextrin interactions were evaluated in the solution for stoichiometry and stability 
constant by phase solubility analysis. Results proved the increased limited water solubility of 
resveratrol-cyclodextrins inclusion complexes. Resveratrol/hydroxy-β-cyclodextrin complex 
also exhibited superior antioxidant potential compared to β-cyclodextrin complex [56].
5.4. Nanocarrier systems
5.4.1. Solid lipid nanoparticles (SLNs)
SLNs are formed by a solid lipid matrix medium, which is stabilized by surfactants in the aque-
ous media, with potential to enhance drug bioavailability. The diameter ranges between 50 and 
1000 nm. SLNs possess various advantages such as target-specific delivery, photo, and acid 
stability for sensitive drugs (Figure 6). SLNs elegantly control drug distribution at cellular, or 
even at subcellular level [57]. Teskac et al. prepared SLNs of resveratrol by melt-emulsification 
process and investigated cellular uptake, transport, and internalization of the drug in keratino-
cytes. Hydrodynamic diameter of loaded SLNs was calculated by photon correlation spectros-
copy that was found to be 180 ± 8 nm. This confirmed the upgraded cellular uptake and cellular 
density of resveratrol by loaded SLNs. As SLNs were observed to concentrate around nuclei, 
it confirms sustained-release of drug, thus improving the bioavailability and stability [58]. 
A comparison is made between resveratrol nanostructured lipid carriers (NLCs) and SLNs 
Figure 5. Structure of cyclodextrin complex.
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prepared by high shear homogenization using compritol 888ATO, myglyol, poloxamer 188, 
and tween 80. A potent antioxidant activity was observed for both formulations at a concentra-
tion of 50 μM, but resveratrol NLCs was observed to penetrate deeper into the skin [59].
Ana et al. developed lipid nanoparticles of resveratrol to increase the oral bioavailability. 
Modified hot homogenization technique was used to prepare resveratrol-loaded lipid 
nanoparticles (SLNs and NLCs). The encapsulation efficiency was found to be high for both 
SLNs and NLCs, with an average around 70%. The existence of solid state of SLNs and NLCs 
at both room (25°C) and body temperature (37°C) was confirmed by DSC studies. In vitro 
release studies performed in shelf storage conditions showed a negligible release of resve-
ratrol over several hours for both systems, which concluded the high stability of both lipid 
nanoparticle systems [60].
5.4.2. Nanosuspension
These are the nanorange colloidal dispersions systems stabilized by surfactants, containing 
poorly water soluble drugs. These systems result in the improvement of bioavailability of the 
drug by improving its solubility. Kobierski et al. prepared nanosuspension of resveratrol in 
the range between 150 and 220 nm for dermal application using high-pressure homogeniza-
tion technique. Nanosuspension showed high solubility and dissolution velocity for resvera-
trol and thus improved bioavailability [46].
5.5. Vesicular systems
Vesicular systems are the drug delivery systems composed of lipophilic polymeric core, and 
lipophobic tail or shell. These systems are capable of encapsulating both hydrophilic and 
Figure 6. Structure of nanocarrier systems.
Novel Drug Delivery Systems of Resveratrol to Bioavailability and Therapeutic Effects
http://dx.doi.org/10.5772/intechopen.79739
35
lipophilic drugs (Figure 7). They are shown to improve the bioavailability of the drug and thus 
enhancing duration of therapeutic activity. Examples of these systems are liposomes, niosomes, 
transfersome, phytosomes, ethosomes, etc. [61].
5.5.1. Liposomes
Liposomes are colloidal vesicular structures prepared from lipids capable of loading both 
lipophilic and hydrophilic drugs. The bioavailability of resveratrol was found to be improved 
by incorporating into liposomes [42]. Caddeo et al. formulated liposomes of resveratrol using 
phosphatidylcholine and oleic acid as penetration enhancers. Deep penetration of the drug 
into the skin was reported by these systems. The antioxidant potential of the resveratrol was 
also found to be unchanged by incorporating the drug into these systems [62]. Park et al. 
investigated chitosan-coated liposomes of resveratrol for improving transdermal delivery of 
the drug. The stability of the liposome was found to be increasing on chitosan coating, by 
preventing aggregation. Franz diffusion cells were used to investigate the transdermal deliv-
ery of uncoated and 0.1% chitosan-coated liposomes with 0.1% resveratrol. The proportions 
of resveratrol that permeated through the animal skin were found to be 40.42 and 30.84% 
for the coated and uncoated liposomes, respectively. This indicated the effective transdermal 
delivery of chitosan-coated liposomes for delaying skin aging using resveratrol [63].
5.5.2. Niosomes
Niosomes are nonionic surfactant vesicular systems comprised of aqueous inner core 
enclosed by nonionic surfactant membrane, thus forming a closed bilayer structure. These 
systems are capable of loading both hydrophilic and hydrophobic drugs. These are prepared 
by hydration of surfactants. Pando et al. formulated resveratrol encapsulated niosomes using 
two stage techniques, mechanical agitation followed by sonication by using two different 
surfactants, span 60 and span 80. The entrapment efficiency and particle size distribution 
of niosomes prepared from span 80 were found better as comparison to noisome prepared 
Figure 7. Vesicular systems.
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from span 60, hence the bioavailability [43]. Poonam Negi et al. prepared niosome employing 
span 80 as surfactant by thin film hydration and ether injection methods at three different 
levels. Selection of best optimized formulation was done on the basis of entrapment efficiency 
(% EE), sedimentation volume, mean particle size, and microscopy. Optical microscopy and 
transmission electron microscope (TEM) confirmed the vesicular and spherical nature of the 
niosomes. Resveratrol entrapped niosomal gel was formulated by gelling in Carbopol 934. Ex 
vivo permeation studies confirmed better permeation and deposition of resveratrol in skin as 
compared to plain resveratrol [64].
5.5.3. Transfersomes and ethosomes
Transfersomes are ultraflexible lipid-based elastic vesicles, while ethosomes are vesicles con-
taining phospholipids, ethanol, and water with the potential to penetrate into intact skin and 
delivering drug into systemic circulation through skin. Topical formulations of resveratrol as 
a potential drug were prepared as a vesicular system. The diameter of nanocarriers was found 
to possess a mean diameter of 83–116 nm with more than 70% encapsulation efficiency [44].
5.6. Nanosponges
Nanosponges are nanometric-range size particles with enclosed cavities, capable of encapsu-
lating both lipophilic and hydrophilic drugs (Figure 8). These systems improve the solubil-
ity of poorly water soluble drugs and thus the bioavailability [65]. Ahmed et al. formulated 
Figure 8. Nanosponges.
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nanosponges of resveratrol by dissolving the reagents in dimethyl sulfoxide at 100°C for 4 h. 
Improvement of the stability and penetration of resveratrol was recorded by this system [66].
5.7. Microspheres
Microspheres are minute spheres comprising of porous/nonporous inner polymeric matrix 
with an outer, porous and regular to nonporous and irregular, polymeric surface (Figure 9). 
Diameter of these structures ranges from 1 to 500 μm. Peng et al. formulated microspheres 
by emulsion chemical crosslinking method using vanillin as a crosslinker. Stable chitosan-
incorporated resveratrol microspheres were prepared. Encapsulation efficiency of resveratrol 
within microspheres was found to be 93.68%. Resveratrol encapsulated within microspheres 
was protected from light and heat compared to the free resveratrol [67].
5.8. Polymeric micelles
This system is made of amphipathic linear polymers formed spontaneously by self-assembly 
in water and a hydrophobic core in which the drug is encapsulated (Figure 10). The size of 
micelles varies from 20–100 nm, so that they do not cross the normal vessel walls, hence have 
a low volume of distribution and decrease the chances of side effects of the drugs. They carry 
various poorly soluble pharmaceutical agents due to their high in vitro and in vivo stability. 
They get accumulated in body areas with compromised vasculature and act as carrier systems 
for drug targeting as they can carry specific ligands on their surface. Katherine E. Washington 
formulated polymeric micelles of doxorubicin (DOX) and resveratrol (RSV), increasing 
loading of DOX. Co-loading of DOX and RSV in amphiphilic diblock copolymer micelles 
of poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG-b-PCL) and poly(ethylene glycol)-b-
poly(γ-benzyl-ε-caprolactone) (PEG-b-PBCL) results in improvement of loading efficiency 
and bioavailability [68].
Figure 9. Microspheres.
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6. Conclusion
A wide variety of researches use resveratrol as a potential candidate for novel drug delivery. 
The present chapter provides detailed information about the novel drug delivery systems of 
resveratrol to bioavailability and therapeutic effects, issues related to drug delivery along 
with the different approaches utilized to improve the bioavailability of the drug. The novel 
drug delivery systems of resveratrol show immense benefits in therapeutic terms by various 
means, for example, by enhancing the solubility and thus the bioavailability, by increasing 
the half-life of the drug, by reducing the side effects and also focused on the target-specific 
delivery, etc. Various reports include microparticles formulation that shows colon-specific 
drug delivery; resveratrol is encapsulated in cyclodextrins to enhance its poor aqueous 
solubility, SLNs possess various advantages such as target-specific delivery, photo and 
acid stability, and nanosponges and nanosuspension systems results in the improvement 
of bioavailability of the drug by improving its solubility. The bioavailability of resveratrol 
was found to be improved by incorporating into liposomes and also improving transdermal 
delivery, vesicular systems such as transfersomes and ethosomes containing phospholipids, 
ethanol, and water with the potential to penetrate into intact skin and delivering drug into 
systemic circulation through skin; polymeric micelles has the capacity to hold drugs, which 
are poorly soluble in aqueous solution, results in enhanced bioavailability of resveratrol and 
also effective to target tumors, and stable chitosan incorporated resveratrol microspheres 
results controlled release and improved stabilization of resveratrol.
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Figure 10. Polymeric micelles.
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